Evaluating crisaborole as a treatment option for atopic dermatitis

References

• Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289.
   PubMed Web of Science ®Google Scholar
• Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131(1):67–73.
   PubMed Web of Science ®Google Scholar
• Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC phase III. J Allergy Clin Immunol. 2009;124(6):1251–1258.
   PubMed Web of Science ®Google Scholar
• Wolter S, Price HN. Atopic dermatitis. Pediatr Clin North Am. 2014;61(2):241–260.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.
   PubMed Web of Science ®Google Scholar
• Margolis JS, Abuabara K, Bilker W, et al. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150(6):593–600.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li W-Q, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30.
   PubMed Web of Science ®Google Scholar
• Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol. 2004;45(1):16–22.
   PubMedGoogle Scholar
• Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73(2):311–318.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4):S65–S76.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–155.
   PubMed Web of Science ®Google Scholar
• Shi VY, Leo M, Hassoun L, et al. Role of sebaceous glands in inflammatory dermatoses. J Am Acad Dermatol. 2015;73(5):856–863.
   PubMed Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191.
   PubMedGoogle Scholar
• Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–241.
   PubMed Web of Science ®Google Scholar
• Morison WL, Parrish JA, Fitzpatrick TB. Oral psoralen photochemotherapy of atopic eczema. Br J Dermatol. 1978;98(1):25–30.
   PubMed Web of Science ®Google Scholar
• Meduri NB, Vandergriff T, Rasmussen H, et al. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed. 2007;23(4):106–112.
   PubMed Web of Science ®Google Scholar
• Clayton TH, Clark SM, Turner D, et al. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28–33.
   PubMed Web of Science ®Google Scholar
• Grundmann-Kollmann M, Behrens S, Podda M, et al. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol. 1999;40(6 Pt 1):995–997.
   PubMedGoogle Scholar
• Bulat V, Situm M, Dediol I, et al. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol. 2011;35(Suppl 2):147–151.
   PubMedGoogle Scholar
• Kraft M, Worm M. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol. 2017;13(4):301–310.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2017;18(6):837–843.
   PubMed Web of Science ®Google Scholar
• Khan KS, Kunz R, Kleijnen J, et al. Five steps to conducting a systematic review. J R Soc Med. 2003;96(3):118–121.
   PubMed Web of Science ®Google Scholar
• Jenuwine ES, Floyd JA. Comparison of medical subject headings and text-word searches in MEDLINE to retrieve studies on sleep in healthy individuals. J Med Libr Assoc. 2004;92(3):349–353.
   PubMed Web of Science ®Google Scholar
• Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc. 2018;106(4):531–541.
   PubMed Web of Science ®Google Scholar
• Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808–814.
   PubMed Web of Science ®Google Scholar
• Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140:633–643.
   PubMed Web of Science ®Google Scholar
• Choi H, Kim D, Nam S, et al. Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice. J Dermatol Sci. 2018;89(3):248–257.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016;75(2):297–305.
   PubMed Web of Science ®Google Scholar
• Phase 2 study of OPA-15406 ointment in pediatric patients with atopic dermatitis. [ cited 2019 Feb 1]. Available from https://clinicaltrials.gov/ct2/show/NCT03018691
   Google Scholar
• FDA approves Eucrisa for eczema. [ cited 2019 Jan 29]. Available from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm
   Google Scholar
• Stein Gold LF, Eichenfield LF. Topical therapy for atopic dermatitis: new and investigational agents. Semin Cutan Med Surg. 2017;36(4S):S99–S102.
   PubMedGoogle Scholar
• International Nonproprietary Names for Pharmaceutical Substances (INN). [ cited 2019 Jan 29]. Available from https://www.who.int/medicines/publications/druginformation/innlists/RL74.pdf.
   Google Scholar
• Nocentini A, Supuran CT, Winum J-Y. Benzoxaborole compounds for therapeutic uses: a patent review (2010–2018). Expert Opin Ther Pat. 2018;28(6):493–504.
   PubMed Web of Science ®Google Scholar
• Zane L, Chanda S, Jarnagin K, et al. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy. 2016;8(8):853–866.
   PubMed Web of Science ®Google Scholar
• Freund YR, Akama T, Alley MRK, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012;586(19):3410–3414.
   PubMed Web of Science ®Google Scholar
• National center for biotechnology information: crisaborole, PubChem compound database. [ cited 2019 Jan 29]. Available from https://pubchem.ncbi.nlm.nih.gov/compound/44591583.
   Google Scholar
• Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Invest Drugs. 2009;10(11):1236–1242. cited 2019 Jan 29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19876791
   PubMedGoogle Scholar
• Highlights of prescribing information. [ cited 2019 Jan 29]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf
   Google Scholar
• Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999;128(7):1393–1398.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Barber R, Baillie GS, Bergmann R. et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Cell Mol Physiol. 2004;287(2):L332–L343.
   PubMed Web of Science ®Google Scholar
• Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.
   PubMedGoogle Scholar
• Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3):S43–S52.
   PubMed Web of Science ®Google Scholar
• Bäumer W, Hoppmann J, Rundfeldt C, et al. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17–26.
   PubMedGoogle Scholar
• Jimenez JL, Punzón C, Navarro J, et al. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther. 2001;299(2):753–759.
   PubMed Web of Science ®Google Scholar
• Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989;59(4):675–680.
   PubMed Web of Science ®Google Scholar
• Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185(11):6413–6419.
   PubMed Web of Science ®Google Scholar
• Kwak HJ, Song JS, Heo JY, et al. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor- B, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther. 2005;315(3):1188–1195.
   PubMed Web of Science ®Google Scholar
• Stork PJS, Dillon TJ. Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions. Blood. 2005;106(9):2952–2961.
   PubMed Web of Science ®Google Scholar
• Mosenden R, Taskén K. Cyclic AMP-mediated immune regulation – overview of mechanisms of action in T cells. Cell Signal. 2011;23(6):1009–1016.
   PubMed Web of Science ®Google Scholar
• Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016;33(4):380–387.
   PubMed Web of Science ®Google Scholar
• Tom WL, Van Syoc M, Chanda S, et al. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 2016;33(2):150–159.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Gebauer K, Spelman L, et al. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14(10):1108–1112.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, et al. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14(12):1394–1399.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–649.
   PubMed Web of Science ®Google Scholar
• Crisaborole – specialist pharmacy service. [ cited 2019 Feb 1]. Available from https://www.sps.nhs.uk/medicines/crisaborole/
   Google Scholar
• Draelos ZD, Stein Gold LF, Murrell DF, et al. Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies. J Drugs Dermatol. 2016;15(2):172–176.
   PubMed Web of Science ®Google Scholar
• Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–613.
   PubMed Web of Science ®Google Scholar
• Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis. JAMA Dermatol. 2017;153(10):1036.
   PubMed Web of Science ®Google Scholar
• Ellis Hon KL, Christy Kam WY, Leung TF, et al. Steroid fears in children with eczema. Acta Paediatr. 2006;95(11):1451–1455.
   PubMed Web of Science ®Google Scholar
• El Hachem M, Gesualdo F, Ricci G, et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017;43(1):22.
   PubMedGoogle Scholar
• Ring J, Möhrenschlager M, Henkel V. The US FDA ‘Black Box’ warning for topical calcineurin inhibitors. Drug Saf. 2008;31(3):185–198.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012 Sep;67(9):1111–1117.
   PubMed Web of Science ®Google Scholar
• Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–425.
   PubMedGoogle Scholar
• AN2728 topical ointment to treat mild-to-moderate plaque-type psoriasis. [ cited 2019 Feb 2]. Available from https://clinicaltrials.gov/ct2/show/NCT01300052
   Google Scholar
• A proof of concept clinical trial evaluating the safety and efficacy of Eucrisa (crisaborole) in patients with seborrheic dermatitis. [ cited 2019 Feb 2]. Available from https://clinicaltrials.gov/ct2/show/NCT03567980
   Google Scholar
• Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56(2):211–216.
   PubMed Web of Science ®Google Scholar
• Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 Pt 3):S67–S73.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57(1):81–83.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Solman L, Williams HC. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol. 2018;178(3):659–662.
   PubMed Web of Science ®Google Scholar